In β-thalassemia patients with iron toxicity

EXJADE Provides Efficacious
Total Body Chelation

Transfusion-Dependant Beta-Thalassemia

Thalassemia is the most common genetic disorder, with an annual birth rate of 94 million for infants who are heterozygous for β-thalassemia and of 60,000 for those who are homozygous.1 Chronic blood transfusions treat the underlying anemia but may lead to iron toxicity.1

EXJADE provides efficacious therapy regardless of cardiac iron loading

Patients with mild-moderate, severe, and no cardiac iron loading benefited from appropriately dosed EXJADE.

The Thalassemia International Federation recommends screening for iron toxicity.
Or visit http://www.thalassaemia.org.cy/publications.jsp

Screening for Iron Toxicity: Thalassemia International Federation Recommendations2
  • Track transfusions
    • Patients who have received 10 to 20 lifetime transfusions are at risk of iron toxicity
  • Screen serum ferritin
    • Serum ferritin levels that are consistently >1000 µg/L are indicative of iron toxicity

LEARN ABOUT THE CONSEQUENCES OF IRON TOXICITY IN β-THALASSEMIA


Learn more

SAFETY PROFILE ACROSS ANEMIAS

Learn more